Biomarkers remain underused in practice–this platform helps raise awareness and education as well as supports greater adoption of biomarker-driven approaches to improve outcomes for prostate cancer patients.
Location
Urologist, START Carolinas Research Center (formerly Carolina Urologic Research Center)
Myrtle Beach, South Carolina
By the numbers
35 years of experience in urology
500+ clinical trials led
606 peer-reviewed publications focused on prostate cancer
Biomarkers remain underused in practice–this platform helps raise awareness and education as well as supports greater adoption of biomarker-driven approaches to improve outcomes for prostate cancer patients.
About Dr Neal Shore
Dr Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the START Carolinas Research Center as well as the Global Director, GU Oncology START Cancer Research.
Dr Shore has conducted more than 500 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 600 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, and has previously served on the boards of the Bladder Cancer Advocacy Network, the Advanced Prostate Cancer Consensus Conference (APCCC) Scientific Steering Committee, Maple Tree Cancer Alliance and the Duke Global Health Institute. He is Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and Co-Chair of the annual American Urological Association (AUA) International Prostate Cancer Forum. He serves/has served on the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP, Everyday Urology–Oncology and World Journal of Urology. He is the Editor-in-Chief of Reviews in Urology. He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.
Key areas of interest
- Genomic testing and molecular stratification in prostate cancer and GU Oncology
- Translating biomarker insights into global practice
- Optimizing global multidisciplinary models of cancer care
Dr Neal Shore has been compensated by AstraZeneca for their time and expertise in contributing to this initiative.
Explore key pages
AKT, protein kinase B; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
